As scrutiny of pharmaceutical pricing intensifies, excessive pricing is emerging as a tangible enforcement risk within European competition law. Using the AbbVie v. PAF case in the Netherlands as a case study, this quick-fire presentation will explore how courts and authorities are reassessing pricing conduct and what this means for your future strategy.
Time:
11:10am - 11:25am
Agenda Track No.:
Track 2
Session Type:
General Session (Presentation)
Force Inline Description:
0